A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose

Yoshimi Tsuda, Christopher J. Parkins, Patrizia Caposio, Friederike Feldmann, Sara Botto, Susan Ball, Ilhem Messaoudi, Luka Cicin-Sain, Heinz Feldmann, Michael A. Jarvis

Research output: Contribution to journalArticlepeer-review

54 Scopus citations

Abstract

Ebola virus (Zaire ebolavirus; EBOV) is a highly lethal hemorrhagic disease virus that most recently was responsible for two independent 2014 outbreaks in multiple countries in Western Africa, and the Democratic Republic of the Congo, respectively. Herein, we show that a cytomegalovirus (CMV)-based vaccine provides durable protective immunity from Ebola virus following a single vaccine dose. This study has implications for human vaccination against ebolaviruses, as well as for development of a 'disseminating' vaccine to target these viruses in wild African great apes.

Original languageEnglish
Pages (from-to)2261-2266
Number of pages6
JournalVaccine
Volume33
Issue number19
DOIs
StatePublished - May 1 2015

Bibliographical note

Publisher Copyright:
© 2015 Elsevier Ltd.

Funding

We thank Dr U. Koszinowski (Max von Pettenkofer-Institute, Ludwig-Maximilians-University, Germany) for providing the pSMfr3 MCMV BAC, and Dr D. Court (NCI-Frederick, MD) for providing the lambda-based recombination system used to construct the original MCMV/ZEBOV-NP CTL construct. We appreciate K. Marshall (VGTI, OR) and J. Bailey (NIAID, MT) for their organization and coordination of animals used in the study. We also thank the members of Rocky Mountain Veterinary Branch (DIR, NIAID , NIH) for assistance with animal care. Finally, we thank Drs H. Ebihara (DIR, NIAID , NIH), A. Marzi (DIR, NIAID , NIH), P. Barry (University of California at Davis, CA), M. Cranfield (Mountain Gorilla Veterinary Project, Baltimore, MD) for insightful discussions. This study was supported by R21 (AI088442) and the Intramural Research Program of the NIAID , NIH ; and University of Plymouth, School of Biomedical and Healthcare Sciences internal funding.

FundersFunder number
National Institutes of Health (NIH)
Plymouth Marjon University
National Institute of Allergy and Infectious DiseasesZIAAI001089, R21AI088442

    Keywords

    • Cytomegalovirus
    • Disseminating
    • Durable
    • Ebola
    • Ebolavirus
    • Great apes
    • Mouse
    • Protection
    • Vaccine

    ASJC Scopus subject areas

    • Molecular Medicine
    • General Immunology and Microbiology
    • General Veterinary
    • Public Health, Environmental and Occupational Health
    • Infectious Diseases

    Fingerprint

    Dive into the research topics of 'A cytomegalovirus-based vaccine provides long-lasting protection against lethal Ebola virus challenge after a single dose'. Together they form a unique fingerprint.

    Cite this